By Chris Wack

NanoVibronix Inc. said it has completed the application process with the Centers for Medicare and Medicaid to receive a reimbursement code for its UroShield and PainShield Plus devices.

The medical-device company said applying for a CMS reimbursement code for UroShield and PainShield Plus is a next step towards seeking to materially increase the number of providers who may prescribe its devices as therapies for patients, particularly Medicare beneficiaries.

NanoVibronix's UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy. UroShield is also intended to decrease pain and discomfort associated with urinary catheter use.

PainShield Plus uses ultrasound therapy for the treatment of pain and various soft tissue injuries either directly over joints or orthopedic hardware and without the need for messy ultrasound gels.

NanoVibronix shares were up 10%, to $2.24, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

August 05, 2021 09:22 ET (13:22 GMT)